Signals Analytics, analytics platform that leverages external data to uncover trends and predictive insights, announced the addition of 1,600 rare diseases, deepening its coverage of medical conditions and therapeutic areas.
The enhancement of rare diseases coverage offers pharmaceutical companies a comprehensive view of this hard-to-capture landscape with relevant insights that can allow opportunities for drug development, repurposing, and partnering.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.